Published in Int J Cancer on February 15, 1989
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Epidemiology of inflammatory breast cancer (IBC). Breast Dis (2006) 2.46
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer (2008) 1.82
Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A (1991) 1.77
Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat (2012) 1.77
The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol (2008) 1.49
Inflammatory breast cancer: what we know and what we need to learn. Oncologist (2012) 1.41
c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer (1991) 1.37
c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer (1991) 1.30
Update on inflammatory breast cancer. Breast Cancer Res (2005) 1.29
ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer (2000) 1.24
Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol (2009) 1.19
Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br J Cancer (1990) 0.93
EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis (2009) 0.92
Simulated annealing with restrained molecular dynamics using CONGEN: energy refinement of the NMR solution structures of epidermal and type-alpha transforming growth factors. Protein Sci (1996) 0.89
p38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion. Neoplasia (2003) 0.81
c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. Br J Cancer (1992) 0.80
Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer (1990) 0.80
Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway. Int J Biol Markers (2012) 0.80
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res (2014) 0.78
Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget (2016) 0.75
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer (1998) 2.57
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A (1995) 2.56
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res (1985) 2.06
Prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer Inst (1998) 2.00
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab (2000) 1.96
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer (1998) 1.96
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg (1998) 1.79
Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol (2004) 1.79
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer (2001) 1.78
Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy: experience of the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys (1985) 1.74
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol (1989) 1.60
Complete nucleotide sequence of minicircle kinetoplast DNA from Trypanosoma equiperdum. Proc Natl Acad Sci U S A (1981) 1.56
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol (2005) 1.54
Electron microscopy of the circular kinetoplastic DNA from Trypanosoma cruzi: occurrence of catenated forms. Proc Natl Acad Sci U S A (1969) 1.49
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med (1996) 1.49
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol (2014) 1.45
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer (2011) 1.36
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol (1995) 1.36
Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer (2001) 1.32
Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J (1996) 1.31
Preparation and properties of nuclear and satellite deoxyribonucleic acid of Trypanosoma cruzi. J Mol Biol (1967) 1.31
Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer (1999) 1.30
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol (2007) 1.29
Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med (1988) 1.25
Replicating, convalently closed, circular DNA from kinetoplasts of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1972) 1.23
The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer (2004) 1.22
Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer (1988) 1.20
Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol (2010) 1.18
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer (2003) 1.17
ATP-independent type II topoisomerase from trypanosomes. Proc Natl Acad Sci U S A (1986) 1.16
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res (1988) 1.16
Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene (1990) 1.16
Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology (1987) 1.15
Retained surgical sponge or gossypiboma of the breast. Eur J Radiol (2002) 1.13
Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage. Biochemistry (1986) 1.11
Breast elasticity: principles, technique, results: an update and overview of commercially available software. Eur J Radiol (2012) 1.10
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab (2003) 1.10
Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst (1989) 1.08
C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet (1987) 1.08
Phospholipase A2 is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells. J Biol Chem (1997) 1.08
Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest (1992) 1.07
Compliance with cotrimoxazole prophylaxis for the prevention of opportunistic infections in HIV-positive tuberculosis patients in Thyolo district, Malawi. Int J Tuberc Lung Dis (2001) 1.07
Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res (1989) 1.06
Absence of kinetoplast DNA in a late antigenic variant of Trypanosoma equiperdum. Mol Biochem Parasitol (1980) 1.06
Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab (1987) 1.05
Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol (1995) 1.05
Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast Cancer Res Treat (1989) 1.05
Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol (1986) 1.05
Arterioureteral fistula after extended resection of pelvic tumors: report of three cases and review of the literature. Ann Vasc Surg (1992) 1.02
Abnormal circular DNA molecules induced by ethidium bromide in the kinetoplast of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1969) 1.02
Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med (1996) 1.02
Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome. J Clin Oncol (1989) 1.01
Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst (1993) 1.01
[Fractionation and characterization of desoxyribonucleic acid (DNA) of trypanosomes (Trypanosoma equiperdum)]. C R Acad Sci Hebd Seances Acad Sci D (1966) 1.00
Conservative management of breast cancer. Br J Surg (1986) 1.00
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer (2006) 1.00
Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res (1993) 0.99
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer (1996) 0.99
Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast. Surg Gynecol Obstet (1991) 0.98
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol (2008) 0.98
Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest (2004) 0.98
c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer (2001) 0.98
The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. J Biol Chem (1996) 0.97
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol (2007) 0.97
Occurrence of a kinetoplast DNA-protein complex in Trypanosoma cruzi. Biochem Biophys Res Commun (1981) 0.97
Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc Res (1999) 0.96
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene (2000) 0.96
Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer (2005) 0.96
Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes. Radiother Oncol (1988) 0.96
Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol (1994) 0.96
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer (2012) 0.95
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol (2002) 0.95
Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol (1995) 0.95
[Induction of a "dyskinetoplast" by ethidium bromide in Trypanosoma cruzi cultivated in vitro]. C R Acad Sci Hebd Seances Acad Sci D (1967) 0.94
Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. Eur J Endocrinol (2009) 0.94
Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res (1991) 0.93
Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res (1994) 0.93
Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br J Cancer (1990) 0.93
c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer (1999) 0.92
[Neurosarcoma associated with Von Recklinghausen disease: apropos of 25 cases observed at the Gustave Roussy Institute from 1967 to 1990]. Bull Cancer (1992) 0.92
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol (1992) 0.92